Cite
APA Citation
Huober, J., Ribi, K., Weder, P., Li, Q., Vanlemmens, L., Gerard, M., Lemonnier, J., Thürlimann, B., Boven, E., & Bonnefoi, H. (n.d.). 150O_PRPertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG). Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100092362247.0x000038